Inovio Pharmaceuticals Inc., a biotechnology company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, has announced a proposed public offering of its common stock or pre-funded warrants, along with Series A and Series B warrants. This underwritten public offering is subject to market conditions and may include a 30-day option for the underwriter to purchase additional shares or warrants. Piper Sandler & Co. is serving as the sole book-running manager. The offering will proceed only through a written prospectus and prospectus supplement, which will be filed with the SEC and made available on their website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。